I own 2,000 shares of KERX. I have been in on this stock for over two years. They have a drug named Zerenex that they are developing that is a possible game changer for dialysis treatment. The P3 results came back at the end of January that shot the stock to as high as $9.90. It is sitting at $7 now. The results were better than expected because there was an iron benefit that no other drug has been able produce. With the iron benefit there is a whole new door that has been opened to pre-dialysis treatment. They are currently in P2 testing on the pre-dialysis treatment.
Now I don't know shit about the bio-tech industry, but some smart people that I know are long on this stock so I am riding their coattails on this one. The Dr. that I know that owns 40,000 shares says this will be a $20 stock in 2 years.
Now I don't know shit about the bio-tech industry, but some smart people that I know are long on this stock so I am riding their coattails on this one. The Dr. that I know that owns 40,000 shares says this will be a $20 stock in 2 years.
Keryx Biopharmaceuticals
(NASDAQ:KERX)
8.75 +0.53 (6.45%)
After Hours: 8.73 -0.02 (-0.23%) May 13, 7:53PM EDT NASDAQ real-time data - Disclaimer Currency in USD
(NASDAQ:KERX)
8.75 +0.53 (6.45%)
After Hours: 8.73 -0.02 (-0.23%) May 13, 7:53PM EDT NASDAQ real-time data - Disclaimer Currency in USD
| Range | 8.11 - 8.75 |
| 52 week | 1.50 - 9.98 |
| Open | 8.20 |
| Vol / Avg. | 4.79M/2.52M |
| Mkt cap | 714.71M |
| P/E | - |
| Div/yield | - |
| EPS | -0.35 |
| Shares | 81.68M |
| Beta | 3.83 |
| Inst. own | 53% |
Keryx Biopharmaceuticals
(NASDAQ:KERX)
11.59 +1.10 (10.49%)
After Hours: 11.54 -0.05 (-0.43%) Oct 17, 7:01PM EDT NASDAQ real-time data - Disclaimer Currency in USD
(NASDAQ:KERX)
11.59 +1.10 (10.49%)
After Hours: 11.54 -0.05 (-0.43%) Oct 17, 7:01PM EDT NASDAQ real-time data - Disclaimer Currency in USD
| Range | 10.70 - 11.79 |
| 52 week | 2.23 - 11.79 |
| Open | 10.70 |
| Vol / Avg. | 9.66M/2.39M |
| Mkt cap | 948.24M |
| P/E | - |
| Div/yield | - |
| EPS | -0.33 |
| Shares | 81.82M |
| Beta | 3.84 |
| Inst. own | 65% |
Keryx Biopharmaceuticals
(NASDAQ:KERX)
15.25 +0.03 (0.20%)
Real-time: 12:35PM EST NASDAQ real-time data - Disclaimer Currency in USD
(NASDAQ:KERX)
15.25 +0.03 (0.20%)
Real-time: 12:35PM EST NASDAQ real-time data - Disclaimer Currency in USD
| Range | 14.84 - 15.39 |
| 52 week | 2.78 - 16.18 |
| Open | 15.19 |
| Vol / Avg. | 2.86M/2.72M |
| Mkt cap | 1.26B |
| P/E | - |
| Div/yield | - |
| EPS | -0.45 |
| Shares | 82.32M |
| Beta | 3.92 |
| Inst. own | 64% |
Keryx's drug Ferric Citrate was approved by the FDA last week. Should be rolled out to dialysis centers in the next 12 weeks.
After approval the stock got some negative press because of wording on their label. It has been totally over blown. This is a $20 stock early next year. The false information being spread by shorts has suppressed the stock down to $14 range.
Now is a great time to buy this stock.
After approval the stock got some negative press because of wording on their label. It has been totally over blown. This is a $20 stock early next year. The false information being spread by shorts has suppressed the stock down to $14 range.
Now is a great time to buy this stock.
[h=1]nsider Selling: Ron Bentsur Sells 70,838 Shares of Keryx Biopharmaceuticals Stock (KERX)[/h] Posted by Kristian Gore on Oct 7th, 2014 // No Comments
Keryx Biopharmaceuticals (NASDAQ:KERX) CEO Ron Bentsur unloaded 70,838 shares of Keryx Biopharmaceuticals stock on the open market in a transaction dated Monday, October 6th. The shares were sold at an average price of $15.88, for a total value of $1,124,907.44. Following the completion of the sale, the chief executive officer
now directly owns 755,977 shares of the company’s stock, valued at approximately $12,004,915. The transaction was disclosed in a document filed with the SEC, which is available at this link.
______________________________________________________________________
[h=1]Keryx Biopharmaceuticals CFO Sells $43,481 in Stock (KERX)[/h] Posted by Scott Davis on Oct 7th, 2014 // No Comments
Keryx Biopharmaceuticals (NASDAQ:KERX) CFO
James F. Oliviero III sold 2,694 shares of the stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $16.14, for a total transaction of $43,481.16. Following the sale, the chief financial officer now directly owns 153,345 shares of the company’s stock, valued at approximately $2,474,988. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
now directly owns 755,977 shares of the company’s stock, valued at approximately $12,004,915. The transaction was disclosed in a document filed with the SEC, which is available at this link. ______________________________________________________________________
[h=1]Keryx Biopharmaceuticals CFO Sells $43,481 in Stock (KERX)[/h] Posted by Scott Davis on Oct 7th, 2014 // No Comments
James F. Oliviero III sold 2,694 shares of the stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $16.14, for a total transaction of $43,481.16. Following the sale, the chief financial officer now directly owns 153,345 shares of the company’s stock, valued at approximately $2,474,988. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.Those insider sales we're all made to satisfy their income tax obligations. Those two vested a shit ton of shares the day their drug (Ferric Citrate) was FDA approved. Nothing more than that. It's right on the form. Pretty poor of the writer to not include it.
"1. Sale of a total of 2,694 shares of common stock was made in order to satisfy Mr. Oliviero's income tax withholding obligation upon the vesting of 5,128 shares of restricted stock on October 2, 2014. Mr. Oliviero had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock."
Seth Klarman (Baupost Group) now owns 20% of Keryx. He bought in his intital 10% in q1 and after q3 he doubled his stake. Take a look at IDIX the only other biotech Klarman owned. Same thing is going to happen to KERX.
"1. Sale of a total of 2,694 shares of common stock was made in order to satisfy Mr. Oliviero's income tax withholding obligation upon the vesting of 5,128 shares of restricted stock on October 2, 2014. Mr. Oliviero had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock."
Seth Klarman (Baupost Group) now owns 20% of Keryx. He bought in his intital 10% in q1 and after q3 he doubled his stake. Take a look at IDIX the only other biotech Klarman owned. Same thing is going to happen to KERX.
